Targeting HER3 in EGFR TKI-resistant EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

Recent technological advancements like antibody-drug conjugates (ADCs) and bispecific antibodies (bsAbs) have improved HER3’s targetability and pharmacological potential.

expert

About the author

Domenique Catalano

Senior Manager

View profile

Get in touch

Have a question or need more detail? Tell us what you’re looking for, and our team will be in touch shortly.

First Name

Last Name

Company

Job Title

Email address

Business phone

How Can We Help

Please check this box to receive communications from Citeline about products, services and content you may find of interest. サイトラインの業界・市場レポートやイベント等最新ニュースを受け取る（無料）

Targeting HER3 in EGFR TKI-resistant EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

About the author

Sitetrove

Trialtrove

Scrip

Get in touch

Targeting HER3 in EGFR TKI-resistant EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)

About the author

Explore related solutions

Sitetrove

Trialtrove

Scrip

Get in touch